Targeting the multidrug resistance-1 transporter in AML: Molecular regulation and therapeutic strategies

Blood

Volumn 104, Issue 7, 2004, Pages 1940-1951

  Mahadevan, Daruka ^a   List, Alan F ^b  

^a UNIVERSITY OF ARIZONA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; CYCLOSPORIN A; CYCLOSPORIN D; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DEXNIGULDIPINE; DEXVERAPAMIL; DOXORUBICIN; GLYCOPROTEIN P; HMN 176; LANIQUIDAR; LONAFARNIB; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN; ONT 093; PROTEIN FARNESYLTRANSFERASE INHIBITOR; QUINIDINE; TAMOXIFEN; TARIQUIDAR; TIPIFARNIB; TRABECTEDIN; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSPODAR; VERAPAMIL; VINCRISTINE; ZOSUQUIDAR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANIMAL MODEL; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CELL SURVIVAL; CHEMOSENSITIVITY; DRUG TARGETING; GASTROINTESTINAL TOXICITY; GENE; GENE EXPRESSION REGULATION; HUMAN; HYPERBILIRUBINEMIA; LEUKEMIA; MAJOR CLINICAL STUDY; MDR 1 GENE; MULTIDRUG RESISTANCE; NAUSEA; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 4644359707     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-07-2490     Document Type: Review

References (118)

1. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta. 1976;455:152-162.
2. Pirker R, Wallner J, Geissler K, et al. MDR1 gene expression and treatment outcome in acute myeloid leukemia. J Natl Cancer Inst. 1991;83:708-712.
3. Campos L, Guyotat D, Archimbaud E, et al. Clinical significance of multidrug resistance P-glycoprotein expression in acute nonlymphoblastic leukemia cells at diagnosis. Blood. 1992;79:473-476.
4. Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group Study. Blood. 1997;89:3323-3329.
5. Samdani A, Vijapurkar U, Grimm MA, et al. Cytogenetics and P-glycoprotein (P-gp) are independent predictors of treatment outcome in acute myeloid leukemia (AML). Leuk Res. 1996;20:175-180.
6. Riordan JR, Ling V. Purification of P-glycoprotein from plasma membrane vesicles of Chinese hamster ovary cell mutants with reduced colchicine permeability. J Biol Chem. 1979;254:12701-12705.
7. Debenham PG, Kartner N, Siminovitch L, Riordan JR, Ling V. DMA-mediated transfer of multiple drug resistance and plasma membrane glycoprotein expression. Mol Cell Biol. 1982:2:881-889.
8. Riordan JR, Deuchars K, Kartner N, Alon N, Trent J, Ling V. Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines. Nature. 1985;316:817-819.
9. Rosenberg MF, Kamis AB, Callaghan R, Higgins CF, Ford RC. Three-dimensional structures of the mammalian multidrug resistance P-glycoprotein demonstrate major conformational changes in the transmembrane domains upon nucleotide binding. J Biol Chem. 2003;278:8294-8299.
10. Chen CJ, Chin JE, Ueda K, et al. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell. 1986;47:381-389.
11. Higgins CF. ABC transporters: from microorganisms to man. Ann Rev Cell Biol. 1992:8:67-113.
12. Klein I, Sarkadi B, Vavadi A. An inventory of the human ABC proteins. Biochimica et Biophysica Acta. 1999:1461:237-262.
13. Holland IB, Blight MA. ABC-ATPases, adaptable energy generators fueling transmembrane movement of a variety of molecules in organisms from bacteria to humans. J Mol Biol. 1999:293:381-399.
14. van Veen HW, Callaghan R, Soceneantu L, Sardini A, Konings WN, Higgins CF. A bacterial antibiotic-resistance gene that complements the human multidrug-resistance P-glycoprotein gene. Nature. 1998;391:291-295.
15. Schmitt L, Tampe R. Structure and mechanism of ABC transporters. Curr Opin Struct Biol. 2002;12:754-760.
16. Chang G, Roth C. Structure of MsbA from E. coli: a homolog of the multidrug resistance ATP binding cassette (ABC) transporters. Science. 2001;293:1793-1800.
17. Locher K, Lee A, Rees D. The E. coli BtuCD structure: a framework for ABC transporter architecture and mechanism. Science. 2002;296:1091-1098.
18. Karow M, Georgopoulos C. The essential Escherichia coli MsbA gene, a multicopy suppressor of null mutations in the htrB gene, is related to the universally conserved family of ATP-dependent translocators. Mol Microbiol. 1993;7:69-79.
19. Schmitt L, Tampe R. Affinity, specificity, diversity: a challenge for the ABC transporter TAP in cellular immunity. Chembiochem. 2000;1:16-35.
20. Tanigawara Y. Role of P-glycoprotein in drug disposition. Ther Drug Monit. 2000;22:137-140.
21. Gallen DF, Baker E, Simmers RN, Seshadri R, Roninson IB. Localization of the human multiple drug resistance gene, MDR1, to 7q21.1. Hum Genet. 1987;77:142-144.
22. Scotto KW, Johnson RA. Transcription of the multidrug resistance gene MDR1: a therapeutic target. Molecular Interventions. 2001;1:117-125.
23. Hirsch-Ernst KI, Ziemann C, Schmitz-Salue C, Foth H, Kahl GF. Modulation of P-glycoprotein and mdr1b mRNA expression by growth factors in primary rat hepatocyte culture. Biochem Biophys Res Commun. 1995;215:179-185.
24. Hirsch-Ernst KI, Ziemann C, Foth H, Kozian D, Schmitz-Salue C, Kahl GF. Induction of mdr1b mRNA and P-glycoprotein expression by tumor necrosis factor alpha in primary rat hepatocyte cultures. J Cell Physiol. 1998;176:506-515.
25. Fardel O, Lecureur V, Daval S, Corlu A, Guillouzo A. Up-regulation of P-glycoprotein expression in rat liver cells by acute doxorubicin treatment. Eur J Biochem. 1997;246:186-192.
26. Thevenod F, Friedmann JM, Katsen AD, Hauser IA. Up-regulation of multidrug resistance P-glycoprotein via nuclear factor-kappaB activation protects kidney proximal tubule cells from cadmium- and reactive oxygen species-induced apoptosis. J Biol Chem. 2000;275:1887-1896.
27. Chin KV, Neda K, Pastan I, Gottesman MM. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science. 1992;255:459-462.
28. Synold TW, Dussault I, Forman BM. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med. 2001;7:584-590.
29. Bush JA, Li G. Regulation of the Mdr1 isoforms in a p53-deficient mouse model. Carcinogenesis. 2002;23:1603-1607.
30. Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC, Colgan SP. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res. 2002;62:3387-3394.
31. Gripe LD, Gelfanov VM, Smith EA, et al. Role for c-jun N-terminal kinase in treatment-refractory acute myeloid leukemia (AML): signaling to multidrug-efflux and hyperproliferation. Leukemia. 2002;16:799-812.
32. Kuo MT, Liu Z, Wei Y, et al. Induction of human MDR1 gene expression by 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase pathway that activate NF-kappaB signaling. Oncogene. 2002;21:1945-1954.
33. Yang JM, Vassil AD, Hait WN. Activation of phospholipase C induces the expression of the multidrug resistance (MDR1) gene through the Raf-MAPK pathway. Mol Pharmacol. 2001;60:674-680.
34. Ding S, Chamberlain M, McLaren A, Goh L, Duncan I, Wolf CR. Cross-talk between signalling pathways and the multidrug resistant protein MDR-1. Br J Cancer. 2001;85:1175-1184.
35. Fine RL, Chambers TC, Sachs CW. P-glycoprotein, multidrug resistance and protein kinase C. Stem Cells. 1996;14:47-55.
36. Pallares-Trujillo J, Lopez-Soriano FJ, Argiles JM. Lipids: a key role in multidrug resistance. Int J Oncol. 2000;16:783-798.
37. Pallis M, Turzanski J, Higashi Y, Russell N. P-glycoprotein in acute myeloid leukaemia: therapeutic implications of its association with both a multidrug-resistant and an apoptosis-resistant phenotype. Leuk Lymphoma. 2002;43:1221-1228.
38. Johnstone RW, Cretney E, Smyth MJ. P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. Blood. 1999;93:1075-1085.
39. Smyth MJ, Krasovskis E, Sutton VR, Johnstone RW. The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. Proc Natl Acad Sci USA. 1998;95:7024-7029.
40. Watts GS, Futscher BW, Isett R, Gleason-Guzman M, Kunkel MW, Salmon SE. cDNA microarray analysis of multidrug resistance: doxorubicin selection produces multiple defects in apoptosis signaling pathways. J Pharmacol Exp Then 2001;299:434-441.
41. Liu YY, Man TY, Giuliano AE, Cabot MC. Ceramide glycosylation potentiates cellular multidrug resistance. FASEB J. 2001;15:719-730.
42. Itoh M, Kitano T, Watanabe M, et al. Possible role of ceramide as an indicator of chemoresistance: decrease of the ceramide content via activation of glucosylceramide synthase and sphingomyelin synthase in chemoresistant leukemia. Clin Cancer Res. 2003;9:415-423.
43. Lehne G, Sorensen DR, Tjonnfjord GE, et al. The cyclosporin PSC 833 increases survival and delays engraftment of human multidrug-resistant leukemia cells in xenotransplanted NOD-SCID mice. Leukemia. 2002;16:2388-2394.
44. Ruefli AA, Tainton KM, Darcy PK, Smyth MJ, Johnstone RW. P-glycoprotein inhibits caspase-8 activation but not formation of the death inducing signal complex (disc) following Fas ligation. Cell Death Differ. 2002;9:1266-1272.
45. Leith CP, Kopecky KJ, Chen IM, et al. Frequency and clinical significance of the multidrug resistance proteins MDR1. P-Glycoprotewin, MRP1, and LRP in acute myeloid leukemia. A Southwest Oncology Group Study. Blood. 1999:94:1086-1099.
46. Beck WT, Grogan TM, Willman CL, et al. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res. 1996;56:3010.
47. Marie JP, Zittoun R, Sikic BI. Multidrug resistance (MDR1) gene expression in adult acute leukemia: correlations with treatment outcome and in vitro drug sensitivity. Blood. 1991;78:586-592.
48. List A, Spier CM, Cline A, et al. Expression of the multidrug resistance gene product (P-glycoprotein) in myelodysplasia is associated with a stem cell phenotype. Br J Haematol. 1991:78:28-34.
49. + acute myeloid leukemia cells. Blood. 1993;82:3157-3162.
50. Paietta E, Andersen J, Racevskis J, et al. Significantly lower P-glycoprotein expression in acute promyelocytic leukemia than in other types of acute myeloid leukemia: immunological, molecular and functional analyses. Leukemia. 1994:8:968-973.
51. List AF. Multidrug resistance: clinical relevance in acute leukemia. Oncology. 1993:7:23-32.
52. Nooter K, Sonneveld P, Oostrum R, Herweijer H, Hagenbeek T, Valerio D. Overexpression of the mdr 1 gene in blast cells from patients with acute myelocytic leukemia is associated with decreased anthracycline accumulation that can be restored by cyclosporin-A. Int J Cancer. 1990;45:263-268.
53. Guerci A, Merlin JL, Missoun N, et al. Predictive value for treatment outcome for acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry. Blood. 1995;8:2147-2153.
54. Linenberger ML, Hong T, Rowers D, et al. Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin. Blood. 2001;98:988-994.
55. Bailly J-D, Muller C, Jaffrezou J-P, et al. Lack of correlation between expression and function of P-glycoprotein in acute myeloid leukemia cell lines. Leukemia. 1995:9:799-807.
56. Musto P, Melillo L, Lombardi G, Matera R, di Giorgio G, Carotenuto M. High risk of early resistant relapse for leukaemic patients with presence of multidrug resistance associated P-glycoprotein positive cells in complete remission. Br J Haematol. 1991:77:50-53.
57. van den Heuvel-Eibrink MM, Wiemer EA, de Boevere MJ, et al. MDR1-gene related clonal selection and P-glycoprotein function and expression in relapsed or refractory acute myeloid leukemia. Blood. 2001;97:3605-3611.
58. van den Heuvel-Eibrink MM, Wiemer EA, Prins A, et al. Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML). Leukemia. 2002;16:833-839.
59. van der Kolk DM, Vellenga E, Scheffer GL, et al. Expression and activity of breast cancer resistance protein (BCRP) in de novo and relapsed acute myeloid leukemia. Blood. 2002:99:3763-3770.
60. van der Kolk DM, de Vries EG, Noordhoek L, et al. Activity with expression of the multidrug resistance protein P-glycoprotein, MRP1, MRP2, MRP3, and MRP5 in de novo and relapsed acute rhyeloid leukemia. Leukemia. 2001:15:1544-1553.
61. Legrand O, Siminon G, Beauchamp-Nicond A, et al. Simultaneous activity of MRP1 and P-gp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute leukemia. Blood. 1999:94:1046-1056.
62. van der Kolk DM, de Vries EG, van Putten WJ, et al. P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia. Clin Cancer Res. 2000;6:3205-3214.
63. List AF, Spier CS, Grogan TM, et al. Overexpression of the major vault transporter protein lung-resistant protein predicts treatment outcome in acute myeloid leukemia. Blood. 1966;87:2464-2469.
64. Legrand O, Perrot JY, Simonin G, et al. Both P-gp and MRP1 activities using calcein-AM contribute to drug resistance in AML. Adv Exp Med Biol. 1999:457:161-175.
65. Nussler V, Pelka-Fleischer R, Zwierzina H, et al. P-glycoprotein- expression expression in patients with acute leukemia: clinical relevance. Leukemia. 1996;10(suppl 3):S23-31.
66. Naito K, Takeshita A, Shigeno K, et al. Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines. Leukemia. 2000;14:1436-1443.
67. Mahon FX, Belloc F, Lagarde V, et al. MDR1 gene overexpressipn confers resistance to imatinib mesylate in leukemia cell line models. Blood. 2003:101:2368-2373.
68. Matsui H, Takeshita A, Naito K, et al. Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers. Leukemia. 2002;16:813-819.
69. Ford J. Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitizers. Eur J Cancer. 1996;32A: 991-1001.
70. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 1981;41:1967-1972.
71. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res. 1982;42:4730-4733.
72. Gaynor ER, Unger JM, Miller TP, et al. Infusional CHOP chemotherapy (CVAD) with or without chemosensitizers offers no advantage over standard CHOP therapy in the treatment of lymphoma: a Southwest Oncology Group Study. J Clin Oncol. 2001;19:750-755.
73. Motzer RJ, Lyn P, Fischer P, et al. Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma. J Clin Oncol. 1995:13:1958-1965.
74. Jiang XR, Kelsey SM, Wu YL, Newland AC. Circumvention of P-glycoprotein-mediated drug resistance in human leukaemic cells by non-immunosuppressive cyclosporin D analogue, SDZ PSC 833. Br J Haematol. 1995:90:375-383.
75. Watanabe T, Tsuge H, Oh-Hara T, Naito M, Tsuruo T. Comparative study on reversal efficacy of SDZ PSC 833, cyclosporin A and verapamil on multidrug resistance in vitro and in vivo. Acta Oncol. 1995:34:235-241.
76. Mistry P, Stewart AJ, Dangerfield W, et al. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res. 2001:61:749-758.
77. Shepard RL, Cao J, Starling JJ, Dantzig AH. Modulation of P-glycoprotein but not MRP1- or BCRP-mediated drug resistance by LY335979. Int J Cancer. 2003;103:121-125.
78. Krishna R, Mayer LD. Modulation of P-glycoprotein (P-gp) mediated multidrug resistance (MDR) using chemosensitizers: recent advances in the design of selective MDR modulators. Curr Med Chem Anti-Cane Agents. 2001;1:163-174.
79. Johnson DR, Finch RA, Lin ZP, Zeiss CJ, Sartorelli AC. The pharmacological phenotype of combined multidrug-resistance mdr1 a/1b- and mrp1-deficient mice. Cancer Res. 2001;61:1469-1476.
80. Sonneveld P, List AF. Chemotherapy resistance in acute myeloid leukaemia. Best Pract Res Clin Haematol. 2001:14:211-233.
81. Marie JP, Bastie JN, Coloma F, et al. Cyclosporin A as a modifier agent in the salvage treatment of acute leukemia (AL). Leukemia. 1993:7:821-824.
82. Solary E, Caillot D, Chauffert B, et al. Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitox-antrone and cytarabine for the treatment of acute leukemia. J Clin Oncol. 1992:10:1730-1736.
83. List AF, Spier C, Greer J, et al. Phase I/II trial of cyclosporine as chemotherapy-resistance modifier in acute leukemia. J Clin Oncol. 1993;11:1652-1660.
84. List AF, Kopecky KJ, Willman CL, et al. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood. 2001;98:3212-3220.
85. List AF, Kopecky KJ, Willman CL, et al. Cyclosporine inhibition of P-glycoprotein in chronic myeloid leukemia blast phase. Blood. 2002:100:1910-1912.
86. Solary E, Witz B, Caillot D, et al. Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study. Blood. 1996:88:1198-1205.
87. Wattell E, Solary E, Hecquet B, et al. Quinine improves results of intensive chemotherapy in myelodysplastic syndromes expressing P-glycoprotein: updated results of a randomized study. Groupe Francais des Myleodysplasies (GFM) and Groupe GOELAMS. Adv Exp Med Biol. 1999;457:35-46.
88. Solary E, Drenau B, Campos L, et al. Quinine as a multidrug resistance inhibitor: a phase 3 multicentric randomized study in adult de novo acute myelogenous leukemia. Blood. 2003:102:1202-1210.
89. Liu Yin JA, Wheatley K, Rees JK, Bumett AK. Comparison of 'sequential' versus 'standard' chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial. Br J Haematol. 2001;113:713-726.
90. Sonneveld P, Bumett A, Vossebeld P, et al. Dose-finding study of valspodar (PSC 833) with daunorubicin and cytarabine to reverse multidrug resistance in elderly patients with previously untreated acute myeloid leukemia. Hematol J. 2000;1:411-421.
91. Chauncey TR, Rankin C, Anderson JE, et al. A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC 833: a Southwest Oncology Group study 9617. Leuk Res. 2000;24:567-574.
92. Dorr R, Karanes C, Spier C, et al. Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia. J Clin Oncol. 2001:9:1589-1599.
93. Gruber A, Bjorkholm M, Brinch L, et al. A phase I/II study of the MDR modulator valspodar (PSC 833) combined with daunorubicin and cytarabine in patients with relapsed and primary refractory acute myeloid leukemia. Leuk Res. 2003;27:323-328.
94. Advani R, Saba HI, Tallman MS, et al. Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (valspodar). Blood. 1999:93:787-795.
95. Greenberg P, Advani R, Tallman M, et al. Treatment of refractory/relapsed AML with PSC833 plus mitoxantrone, etoposide, cytarabine (PSC-MEC) vs MEC: randomized phase III trial (E2995). Blood. 1999;94(suppl 1):383a.
96. Baer MR, George SL, Dodge RK, et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood. 2002;100:1224-1232.
97. Kasimir-Bauer S, Beelen D, Flasshove M, Noppeney R, Seeber S, Scheulen ME. Impact of the expression of P glycoprotein, the multidrug resistance-related protein, bcl-2, mutant p53, and heat shock protein 27 on response to induction therapy and long-term survival in patients with de novo acute myeloid leukemia. Exp Hematol. 2002:30:1302-1308.
98. Cass CE, Janowska-Wieczorek A, Lynch MA, et. al. Effect of duration of exposure to verapamil on vincristine activity against multidrug-resistant human leukemic cell lines. Cancer Res. 1989;49:5798-5804.
99. GM, Chen YN, Mickley LA, et al. P-glycoprotein expression and schedule dependence of adriamycin cytotoxicity in human colon carcinoma cell lines. Int J Cancer. 1991;49:696-703.
100. Slate D, Michelson S. Drug resistance-reversal strategies: comparison of experimental data with model predictions. J Natl Cancer Inst. 1991;83:1574-1580.
101. Politit PM, Arnold ST, Felsted RL, Sinha BK. P-glycoprotein-independent mechanism of resistance to VP-16 in multidrug-resistant tumor cell lines: pharmacokinetic and photoaffinity labeling studies. Molec Pharmacol. 1990:37:790-796.
102. Ross DD, Wooten PJ, Sridhara R, et al. Enhancement of daunorubicin accumulation, retention and cytotoxicity by verapamil or cyclosporin A in blast cells from patients with previously untreated acute myeloid leukemia. Blood. 1993:82:1288-1299.
103. Cole SPC, Sparks KE, Fraser K, et al. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res. 1994:54:5902-5910.
104. Doyle LA, Ross D, Sridhara R, et al. Expression of a 95 kDa membrane protein is associated with low daunorubicin retention in leukemic blast cells. Brit J Cancer. 1995;71:52-58.
105. Doyle LA, Tang W, Abruzzo LV, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA. 1998;95:15665-15670.
106. Iurlaro M, Vacca A, Minischetti M, et al. Antiangiogenesis by cyclosporine. Exp Hematol. 1998;26:1215-1222.
107. Bellamy WT, Richter L, Sirjani D, et al. Vascular endothelial cell growth factor (VEGF) is an autocrine promoter of abnormal localized immature myeloid precursors (ALIP) and leukemia progenitor formation in myelodysplastic syndromes (MDS). Blood. 2001;97:1427-1434.
108. Wandel C, Kim RB, Kajiji S, Guengerich P, Wilkinson GR, Wood AJ. P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. Cancer Res. 1999:59:3944-3948.
109. Goldman B. Multidrug resistance: can new drugs help chemotherapy against cancer. JNCI. 2003;95:255-257.
110. Thomas H, Coley HM. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control. 2003:10:159-165.
111. Gripe L, Tallman M, Karanes C. A phase II trial of zosuquidar (LY335979), a modulator of P-glycoprotein (P-gp) activity, plus daunorubicin and high-dose cytarabine in patients with newly diagnosed secondary acute leukemia (AML), refractory anemia with excess blasts in transformation (REAB-t) or relapsed/refractory AML [abstract]. Blood. 2001;98:595a.
112. Hoover RR, Mahon FX, Melo JV, Daley GQ. Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. Blood. 2002;100:1068-1071.
113. Kabanov AV, Batrakova EV, Alahov VY. Pluonic block copolymers for overcoming drug resistance in cancer. Adv Drug Delivery Reviews. 2002;54:759-779.
114. Pawlak-Roblin C, Tosi PF, Perrin L, et al. Inhibition of multidrug resistance by immunization with synthetic P-glycoprotein-derived peptides. Eur J Caner. 2004;40:606-613.
115. Galimberti S, Guerrini F, Carulli G, et al. Significant co-expression of WT1 and MDR1 genes in acute myeloid leukemia patients at diagnosis. Eur J Haemtol. 2004;72:45-51.
116. Zhu J, Giannola DM, Zhang Y, Rivera AJ, Emerson SG. NF-Y cooperates with USF1/2 to induce the hematopoietic expression of HOXB4. Blood. 2003:102:2420-2427.
117. Zhao J, Bilsland A, Hoare SF, Keith WN. Involvement of NF-Y and Sp1 binding sequences in basal transcription of the telomerase RNA gene. FEBS Lett. 2003:53:111-119.
118. Holm PS, Lage H, Bergmann S, et al. Multidrug resistant cancer cells facilitate E1-independent adenoviral replication: impact for cancer gene therapy. Cancer Res. 2004;64:322-328.